Dandri Maura, Petersen Joerg
I Department of Internal Medicine, University Medical Center Hamburg-Eppendorf German Center for Infection Research, Hamburg-Lübeck-Borstel site.
IFI Institute for Interdisciplinary Medicine, Asklepios Clinic St Georg, Hamburg, Germany.
Clin Infect Dis. 2016 Jun 1;62 Suppl 4(Suppl 4):S281-8. doi: 10.1093/cid/ciw023.
Liver disease associated with persistent infection with hepatitis B virus (HBV) continues to be a major health problem of global impact. Despite the existence of an effective vaccine, at least 240 million people are chronically infected worldwide, and are at risk of developing liver cirrhosis and hepatocellular carcinoma. Although chronic HBV infection is considered the main risk factor for liver cancer development, the molecular mechanisms determining persistence of infection and long-term pathogenesis are not fully elucidated but appear to be multifactorial. Current therapeutic regimens based on the use of polymerase inhibitors can efficiently suppress viral replication but are unable to eradicate the infection. This is due both to the persistence of the HBV genome, which forms a stable minichromosome, the covalently closed circular DNA (cccDNA), in the nucleus of infected hepatocytes, as well as to the inability of the immune system to efficiently counteract chronic HBV infection. In this regard, the unique replication strategies adopted by HBV and viral protein production also appear to contribute to infection persistence by limiting the effectiveness of innate responses. The availability of improved experimental systems and molecular techniques have started to provide new information about the complex network of interactions that HBV establishes within the hepatocyte and that may contribute to disease progression and tumor development. Thus, this review will mostly focus on events involving the hepatocyte: the only target cell where HBV infection and replication take place.
与乙型肝炎病毒(HBV)持续感染相关的肝脏疾病仍然是一个具有全球影响的主要健康问题。尽管存在有效的疫苗,但全球至少有2.4亿人被慢性感染,并有发展为肝硬化和肝细胞癌的风险。虽然慢性HBV感染被认为是肝癌发生的主要危险因素,但决定感染持续存在和长期发病机制的分子机制尚未完全阐明,似乎是多因素的。目前基于使用聚合酶抑制剂的治疗方案可以有效抑制病毒复制,但无法根除感染。这既是由于HBV基因组的持续存在,它在受感染肝细胞的细胞核中形成一个稳定的微型染色体,即共价闭合环状DNA(cccDNA),也是由于免疫系统无法有效对抗慢性HBV感染。在这方面,HBV采用的独特复制策略和病毒蛋白产生似乎也通过限制先天免疫反应的有效性而导致感染持续存在。改进的实验系统和分子技术的出现开始提供有关HBV在肝细胞内建立的复杂相互作用网络的新信息,这些相互作用可能导致疾病进展和肿瘤发展。因此,本综述将主要关注涉及肝细胞的事件:HBV感染和复制发生的唯一靶细胞。